NDT Advance Access originally published online on November 1, 2005
Nephrology Dialysis Transplantation 2006 21(1):20-23; doi:10.1093/ndt/gfi237
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Editorial Comment
Hypertensive myocardial fibrosis
1 Istituto di Medicina Cardiovascolare, 2 Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Universita di Milano, Ospedale Maggiore Policlinico, IRCCS and 3 Istituto Auxologico Italiano IRCCS, Milano, Italy
Correspondence and offprint requests to: C. Cuspidi, Centro Interuniversitario di Fisiologia Clinica e Ipertensione, via F. Sforza 35, 20122 Milano, Italy. Email: dhipertensione@libero.it
Keywords: fibrosis; hypertension; left ventricular hypertrophy
| The first 150 words of the full text of this article appear below. |
| Introduction |
|---|
A variety of cardiac structural and functional changes, such as increased left ventricular mass (LVM), left atrial and aortic root enlargement, LV dysfunction, impairment of coronary reserve and prolonged ventricular repolarization, have been described in patients with long-standing arterial hypertension [1,2]. However, subtle modifications in LV structure and geometry may occur also in the early phases of the natural history of essential hypertension [3]. Among these manifestations of target organ damage, most attention has been devoted to LV hypertrophy (LVH), because the prevalence of this phenotype is relatively high and is associated with an increased risk of cardiovascular morbidity and mortality [4,5].
| Pathophysiology of cardiac fibrosis |
|---|
Normal myocardium is composed of cardiac myocytes, tethered to an extracellular matrix of fibrillar collagen; they represent one-third of all cells, with cells other than cardiomyocytes accounting for the remaining two-thirds [6]. A large body of
| Diagnosis of myocardial fibrosis |
|---|
| Regression of cardiac fibrosis |
|---|
| Conclusions |
|---|
This article has been cited by other articles:
![]() |
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF] |
||||
![]() |
K. Pandya, H.-S. Kim, and O. Smithies Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo PNAS, November 7, 2006; 103(45): 16864 - 16869. [Abstract] [Full Text] [PDF] |
||||

